1
|
Wu T, Wang Y, Shi W, Zhang BQ, Raelson J, Yao YM, Wu HD, Xu ZX, Marois-Blanchet FC, Ledoux J, Blunck R, Sheng JZ, Hu SJ, Luo H, Wu J. A Variant in the Nicotinic Acetylcholine Receptor Alpha 3 Subunit Gene Is Associated With Hypertension Risks in Hypogonadic Patients. Front Genet 2020; 11:539862. [PMID: 33329690 PMCID: PMC7728919 DOI: 10.3389/fgene.2020.539862] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Accepted: 11/10/2020] [Indexed: 12/29/2022] Open
Abstract
Ephb6 gene knockout causes hypertension in castrated mice. EPHB6 controls catecholamine secretion by adrenal gland chromaffin cells (AGCCs) in a testosterone-dependent way. Nicotinic acetylcholine receptor (nAChR) is a ligand-gated Ca2+/Na+ channel, and its opening is the first signaling event leading to catecholamine secretion by AGCCs. There is a possibility that nAChR might be involved in EPHB6 signaling, and thus sequence variants of its subunit genes are associated with hypertension risks. CHRNA3 is the major subunit of nAChR used in human and mouse AGCCs. We conducted a human genetic study to assess the association of CHRNA3 variants with hypertension risks in hypogonadic males. The study cohort included 1,500 hypogonadic Chinese males with (750 patients) or without (750 patients) hypertension. The result revealed that SNV rs3743076 in the fourth intron of CHRNA3 was significantly associated with hypertension risks in the hypogonadic males. We further showed that EPHB6 physically interacted with CHRNA3 in AGCCs, providing a molecular basis for nAChR being in the EPHB6 signaling pathway.
Collapse
Affiliation(s)
- Tao Wu
- Institute of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| | - Yujia Wang
- Research Centre, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.,Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Wei Shi
- Research Centre, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada
| | - Bi-Qi Zhang
- Institute of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| | - John Raelson
- Research Centre, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada
| | - Yu-Mei Yao
- Department of Cardiology, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
| | - Huan-Dong Wu
- Institute of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| | - Zao-Xian Xu
- Institute of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| | | | - Jonathan Ledoux
- Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada
| | - Rikard Blunck
- Department of Physics, University of Montreal, Montreal, QC, Canada
| | - Jian-Zhong Sheng
- Department of Pathology and Physiopathology, College of Medicine, Zhejiang University, Hangzhou, China
| | - Shen-Jiang Hu
- Institute of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| | - Hongyu Luo
- Research Centre, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada
| | - Jiangping Wu
- Research Centre, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.,Nephrology Service, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada
| |
Collapse
|
2
|
Shi W, Ye B, Rame M, Wang Y, Cioca D, Reibel S, Peng J, Qi S, Vitale N, Luo H, Wu J. The receptor tyrosine kinase EPHB6 regulates catecholamine exocytosis in adrenal gland chromaffin cells. J Biol Chem 2020; 295:7653-7668. [PMID: 32321761 PMCID: PMC7261780 DOI: 10.1074/jbc.ra120.013251] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Revised: 04/20/2020] [Indexed: 11/06/2022] Open
Abstract
The erythropoietin-producing human hepatocellular receptor EPH receptor B6 (EPHB6) is a receptor tyrosine kinase that has been shown previously to control catecholamine synthesis in the adrenal gland chromaffin cells (AGCCs) in a testosterone-dependent fashion. EPHB6 also has a role in regulating blood pressure, but several facets of this regulation remain unclear. Using amperometry recordings, we now found that catecholamine secretion by AGCCs is compromised in the absence of EPHB6. AGCCs from male knockout (KO) mice displayed reduced cortical F-actin disassembly, accompanied by decreased catecholamine secretion through exocytosis. This phenotype was not observed in AGCCs from female KO mice, suggesting that testosterone, but not estrogen, contributes to this phenotype. Of note, reverse signaling from EPHB6 to ephrin B1 (EFNB1) and a 7-amino acid-long segment in the EFNB1 intracellular tail were essential for the regulation of catecholamine secretion. Further downstream, the Ras homolog family member A (RHOA) and FYN proto-oncogene Src family tyrosine kinase (FYN)-proto-oncogene c-ABL-microtubule-associated monooxygenase calponin and LIM domain containing 1 (MICAL-1) pathways mediated the signaling from EFNB1 to the defective F-actin disassembly. We discuss the implications of EPHB6's effect on catecholamine exocytosis and secretion for blood pressure regulation.
Collapse
Affiliation(s)
- Wei Shi
- Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
| | - Bei Ye
- Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
- Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
| | - Marion Rame
- Institut des Neurosciences Cellulaires et Intégratives, UPR-3212 Centre National de la Recherche Scientifique and Université de Strasbourg, Strasbourg, France
| | - Yujia Wang
- Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
| | | | | | - Junzheng Peng
- Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
| | - Shijie Qi
- Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
| | - Nicolas Vitale
- Institut des Neurosciences Cellulaires et Intégratives, UPR-3212 Centre National de la Recherche Scientifique and Université de Strasbourg, Strasbourg, France
| | - Hongyu Luo
- Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
| | - Jiangping Wu
- Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
- Nephrology Department, CHUM, Montreal, Quebec, Canada
| |
Collapse
|
3
|
Chalmers J, Woodward M. Observational analyses from ADVANCE and ADVANCE-ON. Diabetes Obes Metab 2020; 22 Suppl 2:19-32. [PMID: 31729126 DOI: 10.1111/dom.13894] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2019] [Revised: 09/27/2019] [Accepted: 10/04/2019] [Indexed: 02/06/2023]
Abstract
AIMS To explain, and document, the epidemiological work associated with the action in diabetes and vascular disease: preterax and diamicron-modified release controlled evaluation (ADVANCE) clinical trial. MATERIALS AND METHODS ADVANCE was designed as a randomized controlled multicentre factorial trial in high-risk patients with diabetes. The two interventions were blood pressure lowering medications versus placebo, and intensive glucose control versus standard glucose control. Following termination of the trial, an observational study of surviving participants, able to join, was mounted: the ADVANCE - observational study (ADVANCE-ON). Other epidemiological analyses that were undertaken treated the trial as a cohort study, including using biomarkers from the blood samples taken from ADVANCE subjects as risk exposures. RESULTS More than 50 publications have reported epidemiological results from ADVANCE. The main results from ADVANCE-ON suggested attenuated benefits of ADVANCE's blood pressure lowering treatment on all-cause and cardiovascular death, but no such long-term benefits for intensive glucose control, although this did give persistent benefit for end-stage renal disease. The other epidemiological studies found, amongst other things, strong effects of NT-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T on macrovascular events, microvascular events and all-cause death. CONCLUSIONS Embedding post-randomization and epidemiological analyses into clinical trials is worthwhile and can be highly productive in advancing scientific knowledge.
Collapse
Affiliation(s)
- John Chalmers
- George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
| | - Mark Woodward
- George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
- George Institute for Global Health, University of Oxford, Oxford, UK
- Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland
| |
Collapse
|
4
|
Shi W, Wang Y, Peng J, Qi S, Vitale N, Kaneda N, Murata T, Luo H, Wu J. EPHB6 controls catecholamine biosynthesis by up-regulating tyrosine hydroxylase transcription in adrenal gland chromaffin cells. J Biol Chem 2019; 294:6871-6887. [PMID: 30824540 PMCID: PMC6497964 DOI: 10.1074/jbc.ra118.005767] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Revised: 02/25/2019] [Indexed: 11/06/2022] Open
Abstract
EPHB6 is a member of the erythropoietin-producing hepatocellular kinase (EPH) family and a receptor tyrosine kinase with a dead kinase domain. It is involved in blood pressure regulation and adrenal gland catecholamine (CAT) secretion, but several facets of EPHB6-mediated CAT regulation are unclear. In this study, using biochemical, quantitative RT-PCR, immunoblotting, and gene microarray assays, we found that EPHB6 up-regulates CAT biosynthesis in adrenal gland chromaffin cells (AGCCs). We observed that epinephrine content is reduced in the AGCCs from male Ephb6-KO mice, caused by decreased expression of tyrosine hydroxylase, the rate-limiting enzyme in CAT biosynthesis. We demonstrate that the signaling pathway from EPHB6 to tyrosine hydroxylase expression in AGCCs involves Rac family small GTPase 1 (RAC1), MAP kinase kinase 7 (MKK7), c-Jun N-terminal kinase (JNK), proto-oncogene c-Jun, activator protein 1 (AP1), and early growth response 1 (EGR1). On the other hand, signaling via extracellular signal-regulated kinase (ERK1/2), p38 mitogen-activated protein kinase, and ELK1, ETS transcription factor (ELK1) was not affected by EPHB6 deletion. We further report that EPHB6's effect on AGCCs was via reverse signaling through ephrin B1 and that EPHB6 acted in concert with the nongenomic effect of testosterone to control CAT biosynthesis. Our findings elucidate the mechanisms by which EPHB6 modulates CAT biosynthesis and identify potential therapeutic targets for diseases, such as hypertension, caused by dysfunctional CAT biosynthesis.
Collapse
Affiliation(s)
- Wei Shi
- From the Research Centre and
| | - Yujia Wang
- From the Research Centre and
- the Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China
| | | | | | - Nicolas Vitale
- the Institut des Neurosciences Cellulaires et Intégratives, UPR-3212, CNRS-Université de Strasbourg, 5 rue Blaise Pascal, 67000 Strasbourg, France, and
| | - Norio Kaneda
- the Department of Analytical Neurobiology, Faculty of Pharmacy, Meijo University, Tempaku, Nagoya 4688503, Japan
| | - Tomiyasu Murata
- the Department of Analytical Neurobiology, Faculty of Pharmacy, Meijo University, Tempaku, Nagoya 4688503, Japan
| | | | - Jiangping Wu
- From the Research Centre and
- Nephrology Department, Centre Hospitalier de l'Université de Montréal Montreal, Quebec, H2X 0A9, Canada
| |
Collapse
|
5
|
Zhang Z, Tremblay J, Raelson J, Sofer T, Du L, Fang Q, Argos M, Marois-Blanchet FC, Wang Y, Yan L, Chalmers J, Woodward M, Harrap S, Hamet P, Luo H, Wu J. EPHA4 regulates vascular smooth muscle cell contractility and is a sex-specific hypertension risk gene in individuals with type 2 diabetes. J Hypertens 2019; 37:775-789. [PMID: 30817459 DOI: 10.1097/hjh.0000000000001948] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
OBJECTIVE We investigated the association of genetic variants of EPHA4, a receptor tyrosine kinase, with hypertension, and its role in vascular smooth muscle cell (VSMC) contractility. METHODS Data from two human genetic studies, ADVANCE and HCHS/SOL, were analyzed for association of EPHA4 single nucleotide variants (SNVs) with hypertension risks. The effect of EPHA4 signalling on mouse VSMC contractility was assessed. RESULTS We identified a SNV (rs75843691 hg19 chr2:g.222395371 C>G), located in the third intron of EPHA4 gene, being significantly associated with hypertension in human female patients (P value = 8.3 × 10, below the Bonferroni-corrected critical P value) but not male patients with type 2 diabetes from the ADVANCE clinical trial. We found that EPHA4 was expressed in VSMCs and its stimulation by anti-EPHA4 antibody led to reduced VSMC contractility. Estrogen enhanced the contractility-lowering effect of EPHA4 stimulation. Conversely, siRNA knockdown of Epha4 expression in VSMCs resulted in increased contractility of VSMCs from female mice but not from male mice. CONCLUSION EPHA4 appears to be a sex-specific hypertension risk gene in type 2 diabetic patients. Forward EPHA4 signalling reduces VSMC contractility, and estrogen is a modifier of this effect. The effect of EPHA4 on VSMCs contractility explains the association of EPHA4 gene with hypertension risks in female patients.
Collapse
Affiliation(s)
- Zeqin Zhang
- Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada
| | - Johanne Tremblay
- Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada
| | - John Raelson
- Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada
| | - Tamar Sofer
- Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Lizhong Du
- The Children's Hospital, Zhejiang University School of Medicine
| | - Qiang Fang
- The Intensive Care Unit, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
| | - Maria Argos
- School of Public Health, University of Illinois at Chicago, Chicago, Illinois, USA
| | | | - Yu Wang
- The Children's Hospital, Zhejiang University School of Medicine
| | - Lingling Yan
- The Children's Hospital, Zhejiang University School of Medicine
| | - John Chalmers
- The George Institute for Global Health, University of Sydney, Sydney, New South Wales, Australia
- The George Institute for Global Health, University of Oxford, Oxford, UK
| | - Mark Woodward
- The George Institute for Global Health, University of Sydney, Sydney, New South Wales, Australia
- The George Institute for Global Health, University of Oxford, Oxford, UK
| | - Stephen Harrap
- Department of Physiology, University of Melbourne, Victoria, Australia
| | - Pavel Hamet
- Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada
| | - Hongyu Luo
- Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada
| | - Jiangping Wu
- Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada
| |
Collapse
|
6
|
Wu T, Zhang BQ, Raelson J, Yao YM, Wu HD, Xu ZX, Marois-Blanchet FC, Tahir MR, Wang Y, Bradley WE, Luo H, Wu J, Sheng JZ, Hu SJ. Analysis of the association of EPHB6, EFNB1 and EFNB3 variants with hypertension risks in males with hypogonadism. Sci Rep 2018; 8:14497. [PMID: 30262919 PMCID: PMC6160468 DOI: 10.1038/s41598-018-32836-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Accepted: 09/14/2018] [Indexed: 12/29/2022] Open
Abstract
Several members of the EPH kinase family and their ligands are involved in blood pressure regulation, and such regulation is often sex- or sex hormone-dependent, based on animal and human genetic studies. EPHB6 gene knockout (KO) in mice leads to hypertension in castrated males but not in un-manipulated KO males or females. To assess whether this finding in mice is relevant to human hypertension, we conducted a human genetic study for the association of EPHB6 and its two ligands, EFNB1 and EFNB3, with hypertension in hypogonadic patients. Seven hundred and fifty hypertensive and 750 normotensive Han Chinese patients, all of whom were hypogonadic, were genotyped for single nucleotide polymorphisms (SNPs) within the regions of the genes, plus an additional 50 kb 5′ of the genes for EPHB6, EFNB1 and EFNB3. An imputed insertion/deletion polymorphism, rs35530071, was found to be associated with hypertension at p-values below the Bonferroni-corrected significance level of 0.0024. This marker is located 5′ upstream of the EFNB3 gene start site. Previous animal studies showed that while male EFNB3 gene knockout mice were normotensive, castration of these mice resulted in hypertension, corroborating the results of the human genetic study. Considering the significant associations of EFNB3 SNPs with hypertension in hypogonadic males and supporting evidence from castrated EFNB3 KO mice, we conclude that loss-of-function variants of molecules in the EPHB6 signaling pathway in the presence of testosterone are protective against hypertension in humans.
Collapse
Affiliation(s)
- Tao Wu
- Institute of Cardiology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China
| | - Bi-Qi Zhang
- Institute of Cardiology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China
| | - John Raelson
- Research Centre, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, H2X 0A9, Canada
| | - Yu-Mei Yao
- Department of Cardiology, Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005, China
| | - Huan-Dong Wu
- Institute of Cardiology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China
| | - Zao-Xian Xu
- Institute of Cardiology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China
| | | | - Muhammad Ramzan Tahir
- Research Centre, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, H2X 0A9, Canada
| | - Yujia Wang
- Research Centre, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, H2X 0A9, Canada.,Children's Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China
| | - W Edward Bradley
- Research Centre, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, H2X 0A9, Canada
| | - Hongyu Luo
- Research Centre, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, H2X 0A9, Canada
| | - Jiangping Wu
- Research Centre, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, H2X 0A9, Canada. .,Nephrology Service, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, H2X 0A9, Canada.
| | - Jian-Zhong Sheng
- Department of Pathology and Physiopathology, College of Medicine, Zhejiang University, Hangzhou, 310005, China.
| | - Shen-Jiang Hu
- Institute of Cardiology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
| |
Collapse
|
7
|
Kim M, Yoo HJ, Kim M, Kim J, Baek SH, Song M, Lee JH. EPHA6 rs4857055 C > T polymorphism associates with hypertension through triglyceride and LDL particle size in the Korean population. Lipids Health Dis 2017; 16:230. [PMID: 29208002 PMCID: PMC5718072 DOI: 10.1186/s12944-017-0620-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2017] [Accepted: 11/22/2017] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Erythropoietin-producing human hepatocellular (Eph) receptors might contribute to the development of atherosclerosis. A genome-wide association study indicated that the Eph receptor A6 gene (EPHA6) associated with at least 1 blood pressure (BP) phenotype. The objective of the present study was to determine whether EPHA6 is a novel candidate gene for hypertension in a Korean population. METHODS A total 2146 study participants with normotension and hypertension were included. Genotype data were obtained using a Korean Chip. To assess the association between single-nucleotide polymorphisms (SNPs) and BP, we performed a linear regression analysis, which showed that rs4850755 in the EPHA6 gene was the SNP most highly associated with both systolic and diastolic BP. RESULTS The presence of the TT genotype of the EPHA6 rs4857055 C > T SNP was associated with a higher risk of hypertension after adjusting for age, sex, body mass index (BMI), smoking, and drinking [odds ratio 1.533, P = 0.001]. In the control group, significant associations were observed between systolic BP and the rs4857055 polymorphism and between diastolic BP and the rs4857055 polymorphism. In the hypertension group, a significant association was observed between systolic BP and the rs4857055 polymorphism. In the hypertension group, subjects with the TT genotype showed significantly higher systolic BP than CC subjects. Additionally, in the hypertension group, TT carriers showed a higher tendency of serum triglyceride (P = 0.069) and significantly higher apolipoprotein B (P = 0.015) and smaller low-density lipoprotein (LDL) particle size (P < 0.001) than either TC or CC subjects. CONCLUSIONS These results could suggest that the EPHA6 rs4857055 C > T SNP is a novel candidate gene for hypertension in the Korean population. Additionally, the TT genotype could be associated with hypertriglyceridemia and small LDL particle size in hypertension.
Collapse
Affiliation(s)
- Minjoo Kim
- Research Center for Silver Science, Institute of Symbiotic Life-TECH, Yonsei University, Seoul, 03722, Korea
| | - Hye Jin Yoo
- Department of Food and Nutrition, Brain Korea 21 PLUS Project, College of Human Ecology, Yonsei University, Seoul, 03722, Korea
| | - Minkyung Kim
- Research Center for Silver Science, Institute of Symbiotic Life-TECH, Yonsei University, Seoul, 03722, Korea
| | - Jiyoo Kim
- Department of Food and Nutrition, Brain Korea 21 PLUS Project, College of Human Ecology, Yonsei University, Seoul, 03722, Korea.,National Leading Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Department of Food and Nutrition, College of Human Ecology, Yonsei University, Seoul, 03722, Korea
| | - Seung Han Baek
- Institute of Convergence Technology, Yonsei University, Seoul, 03722, Korea
| | - Min Song
- Department of Library and Information Science, Yonsei University, Seoul, 03722, Korea
| | - Jong Ho Lee
- Research Center for Silver Science, Institute of Symbiotic Life-TECH, Yonsei University, Seoul, 03722, Korea. .,Department of Food and Nutrition, Brain Korea 21 PLUS Project, College of Human Ecology, Yonsei University, Seoul, 03722, Korea. .,National Leading Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Department of Food and Nutrition, College of Human Ecology, Yonsei University, Seoul, 03722, Korea.
| |
Collapse
|
8
|
Kuang DB, Zhou JP, Li MP, Tang J, Chen XP. Association of NPR3 polymorphism with risk of essential hypertension in a Chinese population. J Clin Pharm Ther 2017; 42:554-560. [PMID: 28497617 DOI: 10.1111/jcpt.12549] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Accepted: 04/05/2017] [Indexed: 12/24/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE Essential hypertension (EH) is a common disease exhibiting large individual difference in occurrence, development and treatment response. Genetic factors are implicated in the development and progression of EH. This study aimed to explore the association between NPR3 single nucleotide polymorphism rs2270915 (A/G, Asn521Asp) and the risk of EH in a Chinese Han population by a case-control study. METHODS The study was a single-centre, case-control trial, in which a total of 287 EH patients and 289 age- and sex-matched healthy controls were enrolled. The inclusion criteria were as follows: Han Chinese origin, male or female patients, systolic blood pressure (SBP) ≥140 mm Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg. The healthy controls were subjects without histories of cardiovascular or cerebrovascular diseases. NPR3 rs2270915 polymorphism was genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). In addition, primary human umbilical vein endothelial cells (HUVECs) were isolated from 19 fresh human umbilical cords and cultured. Atrial natriuretic peptide (ANP) concentration in cell medium was determined by enzyme-linked immunosorbent assay (ELISA). NPR3 mRNA expression was determined by real-time semi-quantitative PCR. RESULTS AND DISCUSSION No significant difference in genotype distribution of NPR3 rs2270915 polymorphism was observed between cases and controls (P>.05). Patients carrying the rs2270915 G allele showed decreased SBP, and the difference was marginal. As compared with cells carrying the rs2270915 AA genotype, those with the AG genotype showed significantly lower NPR3 mRNA expression levels (P<.05) and lower medium ANP concentration (P<.001). WHAT IS NEW AND CONCLUSION This study suggested that NPR3 rs2270915 polymorphism was associated with decreased SBP level marginally in EH patients in a Chinese Han population, and the polymorphism may function through decreasing NPR3 mRNA expression and ANP level.
Collapse
Affiliation(s)
- D-B Kuang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.,Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, China
| | - J-P Zhou
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.,Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - M-P Li
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.,Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, China
| | - J Tang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.,Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, China
| | - X-P Chen
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.,Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, China
| |
Collapse
|